Breathe Well Live Well
Condition: Idiopathic Angioedema
Interventions: Drug: Omalizumab; Drug: Placebos
Sponsors: University of Wisconsin, Madison; Novartis Pharmaceuticals
Not yet recruiting – verified November 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
|
Asthma Drug Xolair Linked to Severe Brain, Heart Issues, Pharmaceutical …
Business Wire (press release) DALLAS–(BUSINESS WIRE)–Xolair, a drug used to treat allergic asthma in adults and children 12 years and older, has been linked to significant health issues such as mini-strokes, heart attacks and blood clots, the national law firm of Baron and Budd … |
View full post on asthma – Google News
|
Research and Markets: Roche/Genentech/Novartis' Asthma Treatment – Xolair …
Business Wire (press release) Roche/Genentech/Novartis' Xolair (omalizumab) is currently the only FDA-approved biologic used in the treatment of asthma. This drug is a recombinant humanized mAb that binds and neutralizes IgE with the same high affinity as its cognate receptor, FceRI. Research and Markets: Merck's Dulera Asthma Treatment – Forecast and Market … |
View full post on asthma – Google News
|
FDA says asthma drug Xolair raises risk of heart, brain problems
MSN Philippines News WASHINGTON – The asthma drug Xolair is associated with a higher risk of heart attack, mini-stroke, chest pain and blood clots in the lungs and veins, among other problems, though the extent of increased risk is unclear, the U.S. Food and Drug … |
View full post on asthma – Google News
Fox News |
FDA slaps cardiovascular warnings on Roche/Novartis asthma blockbuster Xolair
FiercePharma It was way back in 2009 when the FDA first indicated it was worried about reports of heart attacks and strokes in patients taking Xolair, the asthma treatment co-marketed by Novartis ($NVS) and Roche ($RHHBY). Now the agency is taking action, slapping … FDA says asthma drug Xolair raises risk of heart, brain problems Heart, Mini-Stroke Risks From Asthma Drug: FDA FDA adds cardiovascular risks to Xolair label for asthma treatment |
View full post on asthma – Google News
Fox News |
FDA says asthma drug Xolair raises risk of heart, brain problems
Fox News The asthma drug Xolair is associated with a higher risk of heart attack, mini-stroke, chest pain and blood clots in the lungs and veins, among other problems, though the extent of increased risk is unclear, the U.S. Food and Drug Administration said on … |
View full post on asthma – Google News
GlobalPost |
UPDATE 1-FDA says asthma drug Xolair raises risk of heart, brain problems
Reuters Xolair is an injectible drug that was originally approved in 2003 to treat moderate to severe asthma in adults and children aged 12 or over whose condition was not controlled by inhaled steroids. The drug is also approved to treat chronic idiopathic … FDA says asthma drug Xolair raises risk of heart, brain problems FDA warns of increased risks of asthma drug Xolair FDA: Asthma Drug May Increase Risk of CV, Cerebrovascular Events |
View full post on asthma – Google News
GlobalPost |
FDA warns of increased risks of asthma drug Xolair
AAP News (subscription) Patients receiving the asthma medication Xolair (omalizumab) may have a slightly higher risk of serious adverse events affecting the cardiovascular and cerebrovascular systems, according to a review by the Food and Drug Administration (FDA). In … FDA: Asthma Drug May Increase Risk of CV, Cerebrovascular Events |
View full post on asthma – Google News
GlobalPost |
FDA says asthma drug Xolair raises risk of heart, brain problems
Yahoo News WASHINGTON (Reuters) – The asthma drug Xolair is associated with a higher risk of heart attack, mini-stroke, chest pain and blood clots in the lungs and veins, among other problems, though the extent of increased risk is unclear, the U.S. Food and Drug … FDA warns of increased risks of asthma drug Xolair FDA: Asthma Drug May Increase Risk of CV, Cerebrovascular Events |
View full post on asthma – Google News
|
FDA says asthma drug Xolair raises risk of heart, brain problems
Reuters WASHINGTON (Reuters) – The asthma drug Xolair is associated with a higher risk of heart attack, mini-stroke, chest pain and blood clots in the lungs and veins, among other problems, though the extent of increased risk is unclear, the U.S. Food and Drug … FDA: Asthma Drug May Increase Risk of CV, Cerebrovascular Events FDA warns of increased risks of asthma drug Xolair Xolair (omalizumab): Drug Safety Communication – Slightly Elevated Risk of … |
View full post on asthma – Google News